WO2010151688A2 - Capture purification processes for proteins expressed in a non-mammalian system - Google Patents

Capture purification processes for proteins expressed in a non-mammalian system Download PDF

Info

Publication number
WO2010151688A2
WO2010151688A2 PCT/US2010/039854 US2010039854W WO2010151688A2 WO 2010151688 A2 WO2010151688 A2 WO 2010151688A2 US 2010039854 W US2010039854 W US 2010039854W WO 2010151688 A2 WO2010151688 A2 WO 2010151688A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
separation matrix
native
solution
expressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/039854
Other languages
English (en)
French (fr)
Other versions
WO2010151688A3 (en
Inventor
Joseph Edward Shultz
Roger Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43242573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010151688(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to ES10729997T priority Critical patent/ES2862580T5/es
Priority to EP19209054.6A priority patent/EP3660032B1/en
Priority to MX2011013417A priority patent/MX2011013417A/es
Priority to JP2012517737A priority patent/JP2012531428A/ja
Priority to AU2010266093A priority patent/AU2010266093B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to EP10729997.6A priority patent/EP2445924B2/en
Priority to CA2765154A priority patent/CA2765154A1/en
Publication of WO2010151688A2 publication Critical patent/WO2010151688A2/en
Publication of WO2010151688A3 publication Critical patent/WO2010151688A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/32—Extraction; Separation; Purification by precipitation as complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies

Definitions

  • the present invention relates generally to processes for purifying proteins expressed in non-mammalian systems in both non-native soluble and non-native insoluble forms, and more particularly to the direct capture of such proteins from a refold mixture or a cell lysate pool by a separation matrix.
  • Fc-containing proteins are typically expressed in mammalian cells, such as CHO cells.
  • mammalian cells such as CHO cells.
  • affinity chromatography to purify Fc-containing proteins is documented (see, e.g., Shukla et al, (2007) Journal of Chromatography B 848(l):28-39) and is successful, in part, due to the degree of Fc structure observed in proteins expressed in such systems.
  • Fc-containing proteins expressed in non-mammalian cells are often deposited in the expressing cells in limited solubility forms, such as inclusion bodies, that require refolding, and this has been a limiting factor in selecting non- mammalian systems for expressing Fc-containing proteins.
  • the present disclosure addresses these issues by providing simplified methods of purifying proteins comprising Fc regions that are expressed in non-mammalian expression systems in a non-native soluble form or in a non-native insoluble form.
  • This process allows the separation of proteins from cell cultures in highly concentrated pools that can be subsequently refolded at high concentrations and can be of benefit when producing large quantities of protein, particularly since the method is scalable from bench scale, which involves cultures on the order of several liters, up to production scale, which involves cultures of thousands of liters.
  • the disclosed methods can also be employed to purify proteins expressed in a non-native soluble and non-native limited solubility forms in a non-mammalian expression system that have subsequently been derivatized.
  • a protein comprising an Fc region can be associated with a small molecule, such as a toxin.
  • conjugates can be purified using the methods described herein.
  • Protein A means any protein identical or substantially similar to Staphylococcal Protein A, including commercially available and/or recombinant forms of Protein A.
  • Protein A specifically includes engineered Protein A derived media, such as Mab Select SuReTM media (GE Healthcare), in which a single subunit (e.g., the B subunit ) is replicated two or more times and joined in a contiguous sequence to form a recombinant Protein A molecule, and other non-naturally occurring Protein A molecules.
  • the disclosed method can be employed to purify a protein of interest that is expressed in a non-native soluble form in a non-mammalian cell expression system.
  • the protein of interest can be produced by living host cells that either naturally produce the protein or that have been genetically engineered to produce the protein. Methods of genetically engineering cells to produce proteins are known in the art. See, e.g. , Ausabel et al., eds. (1990), Current Protocols in Molecular Biology (Wiley, New York). Such methods include introducing nucleic acids that encode and allow expression of the protein into living host cells.
  • a host cell will be a non-mammalian cell, such as bacterial cells, fungal cells, yeast cells, and insect cells.
  • the lysate was centrifuged in a disc-stack centrifuge to collect the protein in the solid fraction, which was expressed in a limited solubility non- native form, namely as inclusion bodies.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
PCT/US2010/039854 2009-06-25 2010-06-24 Capture purification processes for proteins expressed in a non-mammalian system Ceased WO2010151688A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2765154A CA2765154A1 (en) 2009-06-25 2010-06-24 Capture purification processes for proteins expressed in a non-mammalian system
EP19209054.6A EP3660032B1 (en) 2009-06-25 2010-06-24 Capture purification processes for proteins expressed in a non-mammalian system
MX2011013417A MX2011013417A (es) 2009-06-25 2010-06-24 Procesos de purificacion por captura para proteinas expresadas en un sistema no mamifero.
JP2012517737A JP2012531428A (ja) 2009-06-25 2010-06-24 哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
AU2010266093A AU2010266093B2 (en) 2009-06-25 2010-06-24 Capture purification processes for proteins expressed in a non-mammalian system
ES10729997T ES2862580T5 (es) 2009-06-25 2010-06-24 Procesos de purificación por captura para proteínas expresadas en un sistema no de mamífero
EP10729997.6A EP2445924B2 (en) 2009-06-25 2010-06-24 Capture purification processes for proteins expressed in a non-mammalian system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22047709P 2009-06-25 2009-06-25
US61/220,477 2009-06-25

Publications (2)

Publication Number Publication Date
WO2010151688A2 true WO2010151688A2 (en) 2010-12-29
WO2010151688A3 WO2010151688A3 (en) 2011-05-19

Family

ID=43242573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/039854 Ceased WO2010151688A2 (en) 2009-06-25 2010-06-24 Capture purification processes for proteins expressed in a non-mammalian system

Country Status (12)

Country Link
US (5) US8940878B2 (https=)
EP (2) EP3660032B1 (https=)
JP (1) JP2012531428A (https=)
AU (1) AU2010266093B2 (https=)
CA (1) CA2765154A1 (https=)
DK (1) DK3660032T3 (https=)
ES (2) ES3056593T3 (https=)
FI (1) FI3660032T3 (https=)
LT (1) LT3660032T (https=)
MX (1) MX2011013417A (https=)
SI (1) SI3660032T1 (https=)
WO (1) WO2010151688A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018018011A3 (en) * 2016-07-22 2018-03-01 Amgen Inc. Methods of purifying fc-containing proteins
US10828366B2 (en) 2015-04-22 2020-11-10 Ucb Biopharma Sprl Method of monomerisation of recombinant antibody molecules
WO2022129460A1 (en) 2020-12-18 2022-06-23 Richter Gedeon Nyrt. Methods for the purification of refolded fc-peptide fusion protein

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020621B1 (ru) 2009-06-22 2014-12-30 Амген Инк. Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
LT3660032T (lt) 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
WO2011109556A2 (en) 2010-03-04 2011-09-09 Pfenex Inc. Method for producing soluble recombinant interferon protein without denaturing
US20170101435A1 (en) * 2015-10-13 2017-04-13 Therapeutic Proteins International, LLC Harvesting and perfusion apparatus
WO2019040671A1 (en) * 2017-08-22 2019-02-28 Biogen Ma Inc. METHODS OF PURIFYING ANTIBODIES HAVING REDUCED AGGREGATES OF HIGH MOLECULAR WEIGHT
US11051532B2 (en) 2017-09-22 2021-07-06 Impossible Foods Inc. Methods for purifying protein
CN112839959A (zh) * 2018-09-21 2021-05-25 特尼奥生物股份有限公司 用于纯化异源二聚多特异性抗体的方法
US12011016B2 (en) 2020-09-14 2024-06-18 Impossible Foods Inc. Protein methods and compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7511012B2 (en) 2002-12-20 2009-03-31 Amgen Inc. Myostatin binding agents

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468464A (en) 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
WO1984003711A1 (en) 1983-03-25 1984-09-27 Celltech Ltd A process for the production of a protein
US4468454A (en) 1983-06-10 1984-08-28 E. I. Du Pont De Nemours And Company Antifoggant process
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
GB8508340D0 (en) 1985-03-29 1985-05-09 Creighton T E Production of protein
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
CA1339757C (en) 1987-04-16 1998-03-17 Robert F. Halenbeck Production of purified biologically active, bacterially produced recombinant human csf-1
IL86090A (en) 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
CA1329119C (en) 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
JP2796388B2 (ja) 1988-05-13 1998-09-10 アムジエン・インコーポレーテツド Ｇ−ｃｓｆの精製方法
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5986070A (en) 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
AU664021B2 (en) 1990-09-05 1995-11-02 Natinco Nv Solubilization of proteins in active forms
WO1993018136A1 (en) 1992-03-05 1993-09-16 Cytomed, Inc. Process for supporting hematopoietic progenitor cells
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
EP0657466B1 (en) 1993-11-10 1997-01-15 Pfizer Inc. A process for refolding of (pro-)chymosin, comprising recycling of urea
US5466377A (en) * 1994-01-19 1995-11-14 Grandics; Peter Chromatography media and their uses
IL113497A0 (en) 1994-04-28 1995-07-31 Amgen Inc Method for controlling metallophosphate precipitation in high cell density fermentations
AU2603995A (en) 1994-05-25 1995-12-18 University Of Nebraska Board Of Regents Biologically active glycoprotein hormones produced in procaryotic cells
AU6028396A (en) 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
DE69733950T2 (de) * 1996-01-23 2006-07-06 Ortho-Mcneil Pharmaceutical, Inc. Methode zur reinigung eines erythrpoietinbindenden proteins
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
US6180391B1 (en) 1998-01-28 2001-01-30 Amgen Inc. Highly efficient controlled expression of exogenous genes in e. coli
US6653098B1 (en) 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
JP2003505471A (ja) * 1999-07-21 2003-02-12 アムジエン・インコーポレーテツド Ｖｇｆポリペプチドおよびｖｇｆ関連障害の治療方法
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
DE60138715D1 (de) 2000-09-05 2009-06-25 Amgen Inc Tnf-rezeptor-ähnliche moleküle und deren anwendungen
US20070111944A1 (en) * 2001-02-16 2007-05-17 Scrofani Sergio D B Purification of vascular endothelial growth factor-B
JP2005505494A (ja) 2001-02-23 2005-02-24 イミュネックス・コーポレーション 活性タンパク質の回収増加
US6972327B1 (en) * 2001-05-08 2005-12-06 Immunex Corporation Regeneration of chromatography material
ITMI20012345A1 (it) 2001-11-08 2003-05-08 Internat Ct For Genetic En Gin Procedimento per la produzione di interferone alfa di grado terapeutico
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
AU2002345829A1 (en) 2002-06-24 2004-01-06 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
US7067279B1 (en) 2002-08-23 2006-06-27 Immunex Corporation Cell culture performance with betaine
US7083948B1 (en) 2002-12-24 2006-08-01 Immunex Corporation Polypeptide purification reagents and methods for their use
EP1449848A1 (en) 2003-02-20 2004-08-25 GBF German Research Centre for Biotechnology Method for the production of cystine-knot proteins
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
DE602004026343D1 (de) 2003-10-24 2010-05-12 Amgen Inc Verfahren zur aufreinigung von proteinen in einer durchflussfraktion aus der chromatographie mit hydrophoben wechselwirkungen
US7781395B2 (en) 2004-01-30 2010-08-24 Immunex Corporation Process for purifying proteins
WO2005089102A2 (en) 2004-02-04 2005-09-29 Neose Technologies, Inc. Methods of refolding mammalian glycosyltransferases
US20080124795A1 (en) 2004-03-10 2008-05-29 Hideyuki Miyake Vascular Cell Culture Patterning Substrate
WO2005092914A1 (en) 2004-03-22 2005-10-06 Blue Mountain Technology Development Lab Process for promoting proper folding of human serum albumin using a human serum albumin ligand
FR2874318B1 (fr) 2004-08-19 2006-11-24 Oreal Utilisation en cosmetique de composes polysaccharidiques amphoteres a chaine(s) polymerique(s) cationique(s)
NZ553420A (en) 2004-08-19 2010-02-26 Biogen Idec Inc Refolding transforming growth factor beta family proteins
DE102004041639A1 (de) * 2004-08-27 2006-03-02 Bioceuticals Arzneimittel Ag Verfahren zur Gewinnung von biologisch aktivem humanen G-CSF aus Inclusion Bodies
EA011879B1 (ru) 2004-09-24 2009-06-30 Эмджин Инк. МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ
US7435804B2 (en) 2004-10-19 2008-10-14 Phage Biotechnology, Inc. Method for obtaining single chain antibodies to human interferon α2b
JP5553963B2 (ja) 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
DK1828239T3 (da) 2004-12-10 2011-12-19 Zymogenetics Inc FGF18-produktion i prokaryote værter
CA2594502A1 (en) 2005-01-28 2006-08-03 Zymogenetics Inc. Homogeneous preparations of il-31
WO2006097944A2 (en) 2005-03-17 2006-09-21 Zenotech Laboratories Limited Process for the purification of recombinant granulocyte-colony stimulating factor
DE102005033250A1 (de) * 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7735525B2 (en) 2005-11-14 2010-06-15 Amgen Inc. Thermally insulated apparatus for liquid chromatographic analysis
WO2007075283A2 (en) 2005-12-06 2007-07-05 Amgen Inc. Polishing steps used in multi-step protein purification processes
NZ568809A (en) 2005-12-22 2011-08-26 Genentech Inc Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents
EP1845103B1 (en) 2006-04-10 2015-02-25 Boehringer Ingelheim RCV GmbH & Co KG Method for refolding a protein
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
US20080125580A1 (en) 2006-07-14 2008-05-29 Genentech, Inc. Refolding of Recombinant Proteins
EP2049821A4 (en) 2006-07-21 2013-09-04 Amgen Inc Rupture valve
WO2008097829A2 (en) 2007-02-02 2008-08-14 Neose Technologies, Inc. Large scale production of eukaryotic n-acetylglucosaminyltransferase i in bacteria
TW201307390A (zh) 2007-02-02 2013-02-16 Amgen Inc 海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
WO2008096370A2 (en) 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
WO2008100578A2 (en) 2007-02-14 2008-08-21 Amgen Inc. Method of isolating antibodies by precipitation
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
US20110003337A1 (en) 2008-02-29 2011-01-06 Ramot At Tel-Aviv University Ltd. Immunoglobulin compositions and methods of producing same
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
EA020621B1 (ru) 2009-06-22 2014-12-30 Амген Инк. Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
LT3660032T (lt) 2009-06-25 2026-02-25 Amgen Inc. Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
TWI648532B (zh) 2011-08-29 2019-01-21 美商安美基公司 用於非破壞性檢測-流體中未溶解粒子之方法及裝置
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US20160038588A1 (en) 2013-03-15 2016-02-11 Amgen Inc. Myostatin Antagonism in Human Subjects
US9632095B2 (en) 2014-12-01 2017-04-25 University Of Delaware Device and method for determining reaction kinetics
US9704239B1 (en) 2016-09-02 2017-07-11 Amgen Inc. Video trigger synchronization for improved particle detection in a vessel

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7511012B2 (en) 2002-12-20 2009-03-31 Amgen Inc. Myostatin binding agents

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ARAKAWA ET AL., PROTEIN EXPRESSION & PURIFICATION, vol. 36, no. 2, 2004, pages 244 - 248
AYBAY; IMIR, J. IMMUNOL. METHODS, vol. 233, no. 1-2, 2000, pages 77 - 81
DEVEREUX ET AL., NUCL. ACIDS RES., vol. 12, 1984, pages 387
EJIMA ET AL., ANALYTICAL BIOCHEMISTRV, vol. 345, no. 2, 2005, pages 250 - 257
FORD ET AL., J. CHROMATOGR. B, vol. 754, 2001, pages 427 - 435
GRIBSKOV; BURGESS, NUCL. ACIDS RES., vol. 14, 1986, pages 6745
MILLER; STONE, J. IMMUNOL. METHODS, vol. 24, no. 1-2, 1978, pages 111 - 125
OSTROVE: "Guide to Protein Purification", METHODS IN ENZYMOLOGY, vol. 182, 1990, pages 357 - 379
SHUKLA ET AL., JOURNAL OF CHROMATOGRAPHY B, vol. 848, no. 1, 2007, pages 28 - 39
STOSCHEK: "Quantitation of Protein", "GUIDE TO PROTEIN PURIFICATION," METHODS IN ENZYMOLOGY, vol. 182, 1990, pages 50 - 68
VOLA ET AL., CELL BIOPHYS., vol. 24-25, 1994, pages 27 - 36
WANG ET AL., BIOCHEM. J., vol. 325, 1997, pages 707 - 710
WANG ET AL., BIOCHEM. J., vol. 325, no. 3, 1997, pages 707 - 710
WANG ET AL., BIOCHEMICAL JOURNAL, vol. 325, 1997, pages 707 - 710

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10828366B2 (en) 2015-04-22 2020-11-10 Ucb Biopharma Sprl Method of monomerisation of recombinant antibody molecules
US11786593B2 (en) 2015-04-22 2023-10-17 UCB Biopharma SRL Method of monomerisation of recombinant antibody molecules
WO2018018011A3 (en) * 2016-07-22 2018-03-01 Amgen Inc. Methods of purifying fc-containing proteins
CN109563125A (zh) * 2016-07-22 2019-04-02 美国安进公司 含有Fc的蛋白的纯化方法
US11312745B2 (en) 2016-07-22 2022-04-26 Amgen Inc. Methods of purifying Fc-containing proteins
CN115925780A (zh) * 2016-07-22 2023-04-07 美国安进公司 含有Fc的蛋白的纯化方法
WO2022129460A1 (en) 2020-12-18 2022-06-23 Richter Gedeon Nyrt. Methods for the purification of refolded fc-peptide fusion protein
US12540160B2 (en) 2020-12-18 2026-02-03 Richter Gedeon Nyrt. Methods for the purification of refolded Fc-peptide fusion protein

Also Published As

Publication number Publication date
DK3660032T3 (da) 2025-12-22
EP2445924B1 (en) 2021-03-03
US20100331526A1 (en) 2010-12-30
EP2445924A2 (en) 2012-05-02
AU2010266093A1 (en) 2012-01-19
FI3660032T3 (fi) 2025-12-18
US11407784B2 (en) 2022-08-09
SI3660032T1 (sl) 2026-02-27
ES3056593T3 (en) 2026-02-23
US12312381B2 (en) 2025-05-27
AU2010266093B2 (en) 2013-06-27
MX2011013417A (es) 2012-03-29
EP3660032A1 (en) 2020-06-03
EP2445924B2 (en) 2023-12-13
US10577392B2 (en) 2020-03-03
CA2765154A1 (en) 2010-12-29
WO2010151688A3 (en) 2011-05-19
EP3660032B1 (en) 2025-10-22
US9643997B2 (en) 2017-05-09
ES2862580T3 (es) 2021-10-07
LT3660032T (lt) 2026-02-25
JP2012531428A (ja) 2012-12-10
US20180037603A1 (en) 2018-02-08
US20150361130A1 (en) 2015-12-17
US20200361986A1 (en) 2020-11-19
US8940878B2 (en) 2015-01-27
US20230016430A1 (en) 2023-01-19
ES2862580T5 (es) 2024-06-13

Similar Documents

Publication Publication Date Title
US12312381B2 (en) Capture purification processes for proteins expressed in a non-mammalian system
CA2469815C (en) Methods for purifying protein
KR20110139216A (ko) 소형 모듈형 면역약제 단백질의 정제 방법
US20120077961A1 (en) Enhanced purification of antibodies and antibody fragments by apatite chromatography
WO2013066707A1 (en) Chromatography process for resolving heterogeneous antibody aggregates
JP6385374B2 (ja) タンパク質製剤からエンドトキシンを除去するための物質および方法
TW201617360A (zh) 用於純化蛋白質之方法及試劑
KR20140135959A (ko) 온-컬럼 효소적 절단
Zhang et al. Fusion partners as a tool for the expression of difficult proteins in mammalian cells
WO2011151716A1 (en) Process for the purification of recombinant human il-11
CN112210019A (zh) 一种含单跨膜区的膜蛋白其跨膜区的纯化方法
Giardina Strategies for the purification of recombinant proteins
Many TALON® Metal Affinity Resins User Manual
HK1193617A (en) Cation and anion exchange chromatography method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10729997

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2765154

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010266093

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/013417

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2012517737

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010266093

Country of ref document: AU

Date of ref document: 20100624

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010729997

Country of ref document: EP